2022
Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics
Forray A, Mele A, Byatt N, Tobon A, Gilstad-Hayden K, Hunkle K, Hong S, Lipkind H, Fiellin DA, Callaghan K, Yonkers KA. Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics. PLOS ONE 2022, 17: e0261751. PMID: 35025898, PMCID: PMC8758001, DOI: 10.1371/journal.pone.0261751.Peer-Reviewed Original ResearchConceptsOpioid use disorderPregnant womenUse disordersPrenatal clinicsClinical trialsReproductive health cliniciansCollaborative care approachTRIAL REGISTRATION NUMBERCommunity Healthcare OutcomesMatched-pair clusterPatient treatment engagementTreatment modelObstetric providersOUD treatmentPrimary outcomeObstetrical providersPostpartum womenHealth cliniciansCare approachRegistration numberTreatment engagementRelated treatmentsHealthcare outcomesTrialsWomen
2020
The short-term impact on economic outcomes of SBIRT interventions implemented in reproductive health care settings
Olmstead TA, Martino S, Ondersma SJ, Gilstad-Hayden K, Forray A, Yonkers KA. The short-term impact on economic outcomes of SBIRT interventions implemented in reproductive health care settings. Journal Of Substance Use And Addiction Treatment 2020, 120: 108179. PMID: 33298305, PMCID: PMC7733031, DOI: 10.1016/j.jsat.2020.108179.Peer-Reviewed Original ResearchConceptsReproductive health care settingsHealth care settingsGeneral health care utilizationHealth care utilizationCare settingsE-SBIRTCare utilizationReproductive health care centersRandomized clinical trialsHealth care centersPopulation of womenImpact of screeningMisused prescription medicationsMotor vehicle crashesPublic health perspectiveFuture systematic reviewsSBIRT interventionUsual careRoutine careSBIRT programEconomic outcomesPrescription medicationsCare centerClinical trialsDifferences regression modelsAbstinence outcomes among women in reproductive health centers administered clinician or electronic brief interventions
Yonkers KA, Dailey JI, Gilstad-Hayden K, Ondersma SJ, Forray A, Olmstead TA, Martino S. Abstinence outcomes among women in reproductive health centers administered clinician or electronic brief interventions. Journal Of Substance Use And Addiction Treatment 2020, 113: 107995. PMID: 32359666, PMCID: PMC8372233, DOI: 10.1016/j.jsat.2020.02.012.Peer-Reviewed Original ResearchConceptsElectronic brief interventionBrief interventionUsual careSubstance useAbstinence outcomesEnhanced usual care conditionEnhanced usual careUsual care conditionReproductive health centersRandomized clinical trialsReproductive healthcare servicesReproductive healthcare clinicsE-SBIRTAbstinence ratesPoint prevalenceClinical trialsHealth centersCare conditionsHealthcare clinicsSecondary analysisReproductive healthcareWomenAbstinenceInterventionHealthcare services
2017
Postpartum Contraceptive use and Rapid Repeat Pregnancy Among Women who use Substances
Loree AM, Gariepy A, Ruger JP, Yonkers KA. Postpartum Contraceptive use and Rapid Repeat Pregnancy Among Women who use Substances. Substance Use & Misuse 2017, 53: 162-169. PMID: 28937912, PMCID: PMC6025459, DOI: 10.1080/10826084.2017.1327976.Peer-Reviewed Original ResearchConceptsRapid repeat pregnancyPostpartum contraceptive useRepeat pregnancyContraceptive usePostpartum womenRandomized clinical trialsOB/GYN clinicPrenatal substance exposureEffective contraceptive useIllicit drug useContraceptive initiationWeeks' gestationPregnant womenSubstance use historiesPostpartum contraceptionClinical trialsSubstance exposurePregnancyDrug useSecondary analysisIllicit substancesSubstance useWomenUse historyDepoProvera
2015
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72: 1037-1044. PMID: 26351969, PMCID: PMC4811029, DOI: 10.1001/jamapsychiatry.2015.1472.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderSymptom-onset dosingSerotonin reuptake inhibitorsDays of mensesSSRI withdrawalSymptom onsetSymptomatic daysMenstrual cycleClinical trialsDysphoric disorderOutcome measuresScale scoreSRI treatmentTreatment of PMDDClinical Global Impression ScaleAbrupt treatment cessationDepressive Symptomatology-ClinicianTotal DRSP scoresSecondary outcome measuresPrimary outcome measureGlobal Impression ScaleIDS-C scoresUniversity Medical CenterSertraline hydrochlorideBeginning of menses
2005
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstetrics And Gynecology 2005, 106: 492-501. PMID: 16135578, DOI: 10.1097/01.aog.0000175834.77215.2e.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPlacebo groupSymptom scoresDysphoric disorderNew low dose oral contraceptiveLow-dose oral contraceptivesBehavioral symptom scoresActive treatment groupDaily symptom scoresPhysical symptom scoresEthinyl estradiol groupInactive pillsOral contraceptivesEstradiol groupClinical trialsEthinyl estradiolTreatment cyclesTotal Daily RecordI. EfficacyDrospirenoneSymptomsPill formulationDisordersOCP formulationsPlacebo
2003
Premenstrual disorders: bridging research and clinical reality
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Archives Of Women's Mental Health 2003, 6: 287-292. PMID: 14628181, DOI: 10.1007/s00737-003-0026-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersFemaleHumansPatient Acceptance of Health CarePatient SelectionPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSelf-AssessmentSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeConceptsPremenstrual dysphoric disorderPremenstrual symptomsTreatment resultsBrief Patient Health QuestionnaireConcurrent psychiatric conditionsOb-gyn settingsStatistical Manual IV criteriaSerotonin reuptake inhibitorsUsual care settingsPatient Health QuestionnaireMinor depressive disorderActual clinical practiceTypes of symptomsEligible womenPatient characteristicsReuptake inhibitorsOpen trialSymptomatic subgroupCurrent comorbidityIV criteriaClinical trialsDepressive disorderHealth QuestionnaireTypical patientDysphoric disorder